Repare Therapeutics Inc. (RPTX), Wednesday announced positive initial data from its ongoing Minotaur trial, evaluating lunresertib in combination with Folfiri in patients with advanced solid tumors.
The trial showed an overall response rate of 18.2 percent across tumor types in heavily pretreated patients with tumors, and a clinical benefit of 51.5 percent.
The biotechnology company stated that the primary objectives of the trial were safety and tolerability, and determination of the recommended Phase 2 dose and schedule, whereas secondary objectives were pharmacokinetics, preliminary evidence of anti-tumor activity, pharmacodynamics, and circulating tumor DNA monitoring.
"The encouraging tolerability and early antitumor efficacy data and the potential duration of treatment advantage of the combination of lunresertib plus Folfiri in this heavily pretreated patient population warrant further development in a randomized Phase 2 study," commented Maria Koehler, executive vice president and chief medical officer of Repare.
Currently, Repare's stock is moving down 2.63 percent, to $3.32 on the Nasdaq.
For comments and feedback contact: editorial@rttnews.com
Business News
April 24, 2026 15:15 ET Economics news flow was relatively light this week even as the conflict in the Middle East continued, raising concerns for policymakers. In the U.S., spending data, initial jobless claims and pending home sales were the highlights. Business confidence in the biggest euro area economy was in focus in Europe. Inflation data from Japan gained attention in Asia.